A cyclodextrin-capped histone deacetylase inhibitor

Bioorg Med Chem Lett. 2013 Jun 1;23(11):3346-8. doi: 10.1016/j.bmcl.2013.03.084. Epub 2013 Apr 2.

Abstract

We have synthesized a β-cyclodextrin (βCD)-capped histone deacetylase (HDAC) inhibitor 3 containing an alkyl linker and a zinc-binding hydroxamic acid motif. Biological evaluation (HDAC inhibition studies) of 3 enabled us to establish the effect of replacing an aryl cap (in SAHA (vorinostat,)) 1 by a large saccharidic scaffold "cap". HDAC inhibition was observed for 3, to a lesser extent than SAHA, and rationalized by molecular docking into the active site of HDAC8. However, compound 3 displayed no cellular activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Binding Sites
  • Cell Line, Tumor
  • Histone Deacetylase Inhibitors / chemistry*
  • Histone Deacetylase Inhibitors / metabolism
  • Histone Deacetylases / chemistry*
  • Histone Deacetylases / metabolism
  • Humans
  • Hydroxamic Acids / chemistry
  • Molecular Docking Simulation
  • Protein Isoforms / antagonists & inhibitors
  • Protein Isoforms / metabolism
  • Protein Structure, Tertiary
  • Repressor Proteins / chemistry*
  • Repressor Proteins / metabolism
  • Vorinostat
  • Zinc / chemistry
  • beta-Cyclodextrins / chemistry*
  • beta-Cyclodextrins / metabolism

Substances

  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Protein Isoforms
  • Repressor Proteins
  • beta-Cyclodextrins
  • Vorinostat
  • HDAC8 protein, human
  • Histone Deacetylases
  • Zinc
  • betadex